Ito Masaaki, Hiwasa Takaki, Oshima Yoko, Yajima Satoshi, Suzuki Takashi, Nanami Tatsuki, Sumazaki Makoto, Shiratori Fumiaki, Funahashi Kimihiko, Takizawa Hirotaka, Kashiwado Koichi, Tochigi Naobumi, Shimada Hideaki
Department of Clinical Oncology, Toho University Graduate School of Medicine, Ota-ku, Tokyo 143-8541, Japan.
Department of Neurological Surgery, Chiba University Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan.
Mol Clin Oncol. 2021 Nov;15(5):237. doi: 10.3892/mco.2021.2399. Epub 2021 Sep 20.
Solid cancers have a poor prognosis, and their morbidity and mortality after surgery is high. Even after radical surgery for esophageal cancer, there have been cases of early postoperative death. The present study therefore aimed to explore new tumor markers that can predict the early postoperative prognosis. To identify antibody markers, serological antigens were identified using recombinant cDNA expression cloning (SEREX). The results identified striatin 4 (STRN4) as the antigen recognized by serum IgG antibodies in patients with esophageal cancer. After performing an amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA), it was revealed that when compared with healthy donors, serum anti-STRN4 antibody (STRN4-Ab) levels were significantly higher not only in patients with esophageal cancer but also to lesser extent, in those with gastric cancer, colorectal cancer, lung cancer and breast cancer. Compared with STRN4-Ab-negative patients with esophageal cancer, STRN4-Ab-positive patients had a poorer postoperative prognosis at early stages, suggesting that STRN4-Abs may be useful for predicting poor early-stage prognoses of patients with esophageal cancer. The positive diagnosis rates of esophageal cancer using the STRN4-Ab marker and conventional markers, including squamous cell carcinoma antigen and p53 antibody alone, were 26.4, 35.2 and 19.1% respectively; a result that increased up to 59.1% by combining all three markers. Serum STRN4-Ab may serve as a novel marker of esophageal cancer.
实体癌预后较差，术后发病率和死亡率较高。即使是食管癌根治术后，也有早期术后死亡的病例。因此，本研究旨在探索能够预测术后早期预后的新肿瘤标志物。为了鉴定抗体标志物，采用重组cDNA表达克隆技术（SEREX）鉴定血清学抗原。结果确定striatin 4（STRN4）为食管癌患者血清IgG抗体识别的抗原。在进行放大发光邻近均相分析-联免疫吸附分析（AlphaLISA）后发现，与健康供体相比，不仅食管癌患者血清抗STRN4抗体（STRN4-Ab）水平显著升高，胃癌、结直肠癌、肺癌和乳腺癌患者的血清抗STRN4抗体水平也有不同程度的升高。与STRN4-Ab阴性的食管癌患者相比，STRN4-Ab阳性的患者术后早期预后较差，这表明STRN4-Abs可能有助于预测食管癌患者早期预后不良。单独使用STRN4-Ab标志物和传统标志物（包括鳞状细胞癌抗原和p53抗体）诊断食管癌的阳性率分别为26.4%、35.2%和19.1%；将这三种标志物联合使用时，阳性率可提高至59.1%。血清STRN4-Ab可能是一种新型的食管癌标志物。
